Colitis Clinical Trial
Official title:
GLM Dose Optimisation to Adequate Levels to Achieve Response in Colitis (GOAL-ARC). A Nationwide Multi-centred Randomised Controlled Trial (RCT) Investigating the Use of GLM Dose Adjustment in Ulcerative Colitis (UC).
GLM dose Optimisation to Adequate Levels to Achieve Response in Colitis (GOAL-ARC). A nationwide multi-centred randomised controlled trial (RCT) investigating the use of GLM dose adjustment in ulcerative colitis (UC). The primary objective is to ascertain if dose adjustment of GLM based on GLM drug levels and FCP levels results in higher response and remission rates than standard SmPC dosing.
UC is a chronic inflammatory bowel disease (IBD) in which the lining of the large intestine
become inflamed. There is no official database which gives accurate figures but it is thought
that at least 20,000 people are living with IBD in Ireland. Males and females are affected
equally and patients can be diagnosed at any age, including babies and children. The peak age
of incidence is between the ages of 15 and 35, with a second (smaller) peak from the 50s to
70s.
GLM is a human IgG1κ monoclonal antibody produced by a murine hybridoma cell line with
recombinant DNA technology. It is part of the immunosuppressants pharmacotherapeutic group of
TNF-α inhibitors. It is licensed for use in several chronic inflammatory conditions including
UC, Psoriatic arthritis, axial spondylitis, rheumatoid arthritis.
The design of GOAL-ARC aims to address the impact of dose escalation of GLM immediately
following induction and during the subsequent maintenance phase in response to suboptimal
drugs levels or persisting inflammatory burden as represented by raised faecal calprotectin
(FCP). FCP has been shown to correlate closely to endoscopic disease activity6.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00272818 -
Study to Identify Non-Invasive Markers of Gastrointestinal Allergy
|
||
| Completed |
NCT01369355 -
A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)
|
Phase 3 | |
| Completed |
NCT02709213 -
Determination of the Aetiologies of Acute Colitis and Early Identification of Patients Requiring Diagnostic Colonoscopy
|
||
| Completed |
NCT00533078 -
Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies
|
Phase 2 | |
| Terminated |
NCT00184171 -
Treatment of Microscopic Colitis
|
N/A | |
| Recruiting |
NCT05333978 -
Optoacoustic Detection of Inflammation Using MSOT Device
|
N/A | |
| Not yet recruiting |
NCT06424769 -
Improving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology and Enhanced Disease Management
|
N/A | |
| Recruiting |
NCT02768038 -
Intestinal Microbiome and Chronic Inflammatory Bowel Disease
|
||
| Recruiting |
NCT04272307 -
MIcroorganisms as Triggers in Acute Severe Ulcerative Colitis and Their Influence on Medical Therapy Efficacy: a Multi-omics Pilot Approach.
|
||
| Completed |
NCT05514561 -
FIT and Fecal Calprotectin in Patients With Chronic Lower GI Symptoms
|
||
| Completed |
NCT00072943 -
A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease
|
Phase 2 | |
| Completed |
NCT02647866 -
Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis
|
Phase 2 | |
| Completed |
NCT01326013 -
A Two-Arm, Multi-Centre Clinical Evaluation of the xTAG Gastrointestinal Pathogen Panel
|
Phase 2 | |
| Not yet recruiting |
NCT05726396 -
A Pilot Study Testing the Safety and Feasibility of Restorative Microbiota Therapy (RMT) in Patients With Refractory Immune-checkpoint Inhibitor-related Colitis
|
Phase 2 | |
| Completed |
NCT05414552 -
ECP for Immune-related Adverse Events After Checkpoint Inhibitor Treatment
|
||
| Recruiting |
NCT04407247 -
Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma
|
Phase 1/Phase 2 | |
| Completed |
NCT01369329 -
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
|
Phase 3 | |
| Completed |
NCT01369342 -
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)
|
Phase 3 | |
| Terminated |
NCT00936585 -
NIH Substudy of AIN457 (Anti-IL-17 Monoclonal Antibody) for Treatment of Moderate to Severe Crohn's Disease
|
N/A | |
| Completed |
NCT06074874 -
Intestinal Biomarker Analysis After ECP for ICI Colitis
|